-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

ASH ISTH NHF WFH Guidelines on VWD: Impact on Patients, Policy, and Allied Health Professionals

PhD Trainee
Program: Special-Interest Sessions
Hematology Disease Topics & Pathways:
Research, Bleeding and Clotting, Clinical Practice (Health Services and Quality), Clinical Research, health outcomes research, Workforce, health disparities research, Diversity, Equity, and Inclusion (DEI) , patient-reported outcomes, Diseases, real-world evidence, Therapies, clinical procedures, Adverse Events, VWD, Technology and Procedures
Monday, December 12, 2022: 4:30 PM-6:00 PM
265-268 (Ernest N. Morial Convention Center)
Nathan T. Connell, MD, MPH, Brigham and Women's Hospital
Connell: Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; Doximity: Current equity holder in publicly-traded company; Genentech: Membership on an entity's Board of Directors or advisory committees.
During this special education session, presenters will discuss the ASH ISTH NHF WFH guidelines on the diagnosis and management of von Willebrand disease, which were developed by leading clinical, methodological, and patient experts through a rigorous process to review evidence and write actionable recommendations. The focus of this session will be on how these guidelines impact the development of policy and how they impact the provision of care from both the patient and allied health professional perspectives. 

Jean Grow, jean.grow@gmail.com

Marquette University, Milwaukee, WI; GROW - a DEI consultancy, Milwaukee

Leonard A. Valentino, MD

National Hemophilia Foundation, New York, NY

Penni Smith, BSN

Utah Center for Bleeding and Clotting Disorders, Primary Children's Hospital, Salt Lake City, UT